Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Monash University, Parkville, Victoria 3052, Australia.
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Monash University, Parkville, Victoria 3052, Australia; Department of Toxicology and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 1417614411, Iran.
Cell Signal. 2018 Jan;42:54-66. doi: 10.1016/j.cellsig.2017.09.023. Epub 2017 Sep 29.
Recruitment and activation of brite (or beige) adipocytes has been advocated as a potential avenue for manipulating whole-body energy expenditure. Despite numerous studies illustrating the differences in gene and protein markers between brown, brite and white adipocytes, there is very little information on the adrenergic regulation and function of these brite adipocytes. We have compared the functional (cyclic AMP accumulation, oxygen consumption rates, mitochondrial function, glucose uptake, extracellular acidification rates, calcium influx) profiles of mouse adipocytes cultured from three contrasting depots, namely interscapular brown adipose tissue, and inguinal or epididymal white adipose tissues, following chronic treatment with the peroxisome proliferator-activated receptor γ (PPARγ) agonist rosiglitazone. Prototypical brown adipocytes readily express β-adrenoceptors, and β-adrenoceptor stimulation increases cyclic AMP accumulation, oxygen consumption rates, mitochondrial function, glucose uptake, and extracellular acidification rates. Treatment of brown adipocytes with rosiglitazone increases uncoupling protein 1 (UCP1) levels, and increases β-adrenoceptor mitochondrial function but does not affect glucose uptake responses. In contrast, inguinal white adipocytes only express UCP1 and β-adrenoceptors following rosiglitazone treatment, which results in an increase in all β-adrenoceptor-mediated functions. The effect of rosiglitazone in epididymal white adipocytes, was much lower compared to inguinal white adipocytes. Rosiglitazone also increased α-adrenoceptor mediated increases in calcium influx and glucose uptake (but not mitochondrial function) in inguinal and epididymal white adipocytes. In conclusion, the PPARγ agonist rosiglitazone promotes the induction and function of brite adipocytes cultured from inguinal and epididymal white adipose depots.
米色(或 beige)脂肪细胞的募集和激活被认为是一种调节全身能量消耗的潜在途径。尽管有许多研究表明棕色、米色和白色脂肪细胞之间在基因和蛋白标志物上存在差异,但关于这些米色脂肪细胞的肾上腺素能调节和功能的信息却很少。我们比较了从小鼠三个不同部位培养的脂肪细胞的功能(环腺苷酸积累、耗氧量、线粒体功能、葡萄糖摄取、细胞外酸化率、钙内流)特征,这些部位分别是肩胛间棕色脂肪组织、腹股沟或附睾白色脂肪组织,这些细胞在经过过氧化物酶体增殖物激活受体 γ(PPARγ)激动剂罗格列酮的慢性处理后。典型的棕色脂肪细胞容易表达β-肾上腺素能受体,β-肾上腺素能受体刺激增加环腺苷酸积累、耗氧量、线粒体功能、葡萄糖摄取和细胞外酸化率。罗格列酮处理棕色脂肪细胞会增加解偶联蛋白 1(UCP1)的水平,并增加β-肾上腺素能受体的线粒体功能,但不会影响葡萄糖摄取反应。相比之下,腹股沟白色脂肪细胞仅在罗格列酮处理后表达 UCP1 和β-肾上腺素能受体,这导致所有β-肾上腺素能受体介导的功能增加。与腹股沟白色脂肪细胞相比,罗格列酮在附睾白色脂肪细胞中的作用要低得多。罗格列酮还增加了腹股沟和附睾白色脂肪细胞中α-肾上腺素能受体介导的钙内流和葡萄糖摄取的增加(但不增加线粒体功能)。总之,PPARγ 激动剂罗格列酮促进了腹股沟和附睾白色脂肪组织来源的米色脂肪细胞的诱导和功能。